High levels of circulating osteopontin in inflammatory lung disease regardless of Sars-CoV-2 infection

Giuseppe Cappellano; Hugo Abreu; Davide Raineri; Lorenza Scotti; Luigi Castello; Rosanna Vaschetto; Annalisa Chiocchetti

doi:10.15252/emmm.202114124

High levels of circulating osteopontin in inflammatory lung disease regardless of Sars-CoV-2 infection

EMBO Mol Med. 2021 May 7;13(5):e14124. doi: 10.15252/emmm.202114124. Epub 2021 Mar 31.

Authors

Giuseppe Cappellano^{1

2}, Hugo Abreu^{1

2}, Davide Raineri^{1

2}, Lorenza Scotti³, Luigi Castello^{3

4}, Rosanna Vaschetto³, Annalisa Chiocchetti^{1

2}

Affiliations

¹ Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, Novara, Italy.
² Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del Piemonte Orientale, Novara, Italy.
³ Department of Translational Medicine, Universita' del Piemonte Orientale, Novara, Italy.
⁴ Emergency Department, "Maggiore della Carità" University Hospital, Novara, Italy.

Abstract

This study independently confirms increased levels of osteopontin in COVID-19 patients but also suggests that osteopontin cannot be used as a biomarker of SARS-CoV-2 infection, as elevated levels of circulating osteopontin are found in inflammatory lung disease regardless of SARS-CoV-2 infection.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

COVID-19*
Energy Metabolism
Humans
Mitochondria
Monocytes
Osteopontin
SARS-CoV-2*

Substances

Osteopontin

Abstract

Publication types

MeSH terms

Substances

Grants and funding